StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Protagonist Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $131.20M, up 231.8% year over year. For fiscal 2025 it was $57.67M, down 68.7% from the year before. The highest annual figure on record is $184.15M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$57.67M-68.7%
FY2024Dec 31, 2024$184.15M–
FY2023Dec 31, 2023-$70.24M–
FY2022Dec 31, 2022-$108.14M–
FY2021Dec 31, 2021-$107.87M–
FY2020Dec 31, 2020-$72.48M–
FY2019Dec 31, 2019-$41.53M–
FY2018Dec 31, 2018-$49.95M-1390.0%
FY2017Dec 31, 2017$3.87M–
FY2016Dec 31, 2016-$29.97M–
FY2015Dec 31, 2015-$14.39M–
FY2014Dec 31, 2014-$7.74M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$219.05M–
Q1 FY2026Mar 31, 2026-$48.94M-139.0%
Q4 FY2025Dec 31, 2025-$36.98M–
Q3 FY2025Sep 30, 2025-$1.94M–
Q2 FY2025Jun 30, 2025-$28.78M-110.7%
Q1 FY2025Mar 31, 2025$125.36M–
Q4 FY2024Dec 31, 2024-$29.18M-272.0%
Q3 FY2024Sep 30, 2024-$27.86M–
Q2 FY2024Jun 30, 2024$268.62M–
Q1 FY2024Mar 31, 2024-$27.43M–
Q4 FY2023Dec 31, 2023$16.96M–
Q3 FY2023Sep 30, 2023-$26.61M–
Q2 FY2023Jun 30, 2023-$26.24M–
Q1 FY2023Mar 31, 2023-$34.35M–
Q4 FY2022Dec 31, 2022-$31.64M–
Q3 FY2022Sep 30, 2022-$25.20M–
Q2 FY2022Jun 30, 2022-$13.64M–
Q1 FY2022Mar 31, 2022-$37.67M–
Q4 FY2021Dec 31, 2021-$26.94M–
Q3 FY2021Sep 30, 2021-$28.47M–
Q2 FY2021Jun 30, 2021-$23.70M–
Q1 FY2021Mar 31, 2021-$28.76M–
Q4 FY2020Dec 31, 2020-$18.87M–
Q3 FY2020Sep 30, 2020-$16.29M–
Q2 FY2020Jun 30, 2020-$21.48M-685.3%
Q1 FY2020Mar 31, 2020-$15.85M–
Q4 FY2019Dec 31, 2019-$14.29M–
Q3 FY2019Sep 30, 2019-$14.25M–
Q2 FY2019Jun 30, 2019$3.67M–
Q1 FY2019Mar 31, 2019-$16.66M–
Q4 FY2018Dec 31, 2018-$10.14M–
Q3 FY2018Sep 30, 2018-$9.28M-122.8%
Q2 FY2018Jun 30, 2018-$15.40M–
Q1 FY2018Mar 31, 2018-$15.14M–
Q4 FY2017Dec 31, 2017-$14.15M–
Q3 FY2017Sep 30, 2017$40.70M–
Q2 FY2017Jun 30, 2017-$12.33M–
Q1 FY2017Mar 31, 2017-$10.36M–
Q4 FY2016Dec 31, 2016-$9.68M–
Q3 FY2016Sep 30, 2016-$6.98M–

More Protagonist Therapeutics figures

See a number that looks wrong?